Proteins fold into their functional 3鄄 dimensional structures from a linear amino acid sequence. In vitro this process is spontaneous; while in vivo it is orchestrated by a specialized set of proteins, called chaperones. Protein folding is an ongoing cellular process, as cellular proteins constantly undergo synthesis and degradation. Here emerging links between this process and cancer are reviewed. This perspective both yields insights into the current struggle to develop novel cancer chemotherapeutics and has implications for future chemotherapy discovery.
Introduction
Citing statistics from the American Cancer Society, Harold Varmus noted that we have made depressingly little progress in combating cancer [1] . While over the past 50 years dramatic strides have been made against cardiovascular and infectious diseases, ageadjusted mortality in patients with cancer has declined only slightly, with the decrease mostly related to the drop in lung cancercaused deaths due to aggressive efforts to discourage cigarette smoking.
The discovery of the first oncogene in 1976 [2] triggered a wave of discoveries into oncogenes (genes which increase the risk of developing cancer when mutated) and tumor suppressor genes (TSGs, genes which typically appear in pathways controlling cell growth and regulation). In succeeding decades, these insights were exploited by drug discovery researchers, aiming to displace standard chemotherapeutic drugs (empirically discovered 野cytotoxics冶) with agents targeting oncogenes (molecular targeted drugs). This approach led to one notable success, Novartis爷 Gleevec for chronic myelogenous leukemia (CML), a disease linked to the Philadelphia chromosome, an aberration of chromosomes 9 and 22. Overall, however, the new wave of chemotherapeutic research has been described by researchers at the DanaFarber Cancer Institute as 野neocytotoxics冶 [3] , a reference to their tendency to show unacceptable toxicity at therapeutic doses like the older drugs. This relative lack of success in discovering novel chemotherapeutic drugs prompts the questions of how well we really understand the basic mechanisms underlying cancer and whether there are other avenues of exploration worthy of greater attention. In this review, I focus on the intertwined mechanisms of protein folding and proteostasis and on the balance between production and destruction of proteins in cells. What draws our attention here are two distinct advances: first, the recent clinical successes of Velcade (bortemozib), a drug that inhibits the protein destruction pathway, which was approved in 2003 by the Food and Drug Administration (FDA) of the US for use in refractory multiple myeloma [4] ; and second, the multiplicity of HSP90 inhibitors in phase II clinical trials (HSP90 is one of the chaperone proteins intimately involved in protein folding mechanisms) [5] . Based on these developments and a better understanding of protein homeostasis, I aim here to provide information that may lead to a novel perspective on cancer, with a focus on the dynamic state of the proteome as it relates to cancer. This perspective yields intriguing insights into why so little progress has been made in the development of cancer chemotherapies and indicates alternative directions. In particular, this perspective provides a focus on the work of Whitesell and Lindquist who have proposed, in essence, a novel theory of cancer [6] , asserting that cancer cells acquire a hypermutating phenotype and further claiming that control of cancer will best be achieved by modulating cells爷 ability to adapt and evolve in response to selection pressures.
One can best understand and appreciate this perspective after an overview of basic biochemical and cellular processes. I start with a review of protein folding, describing the spontaneous process by which a linear chain of amino acids acquires the precise threedimensional (3D) structure required for the protein爷s function. Next, I describe how this folding occurs in the crowded and chaotic internal environment of the cell: this is not a simple spontaneous process; rather, this process is mediated by a class of proteins, chaperones or heatshock proteins (HSPs), as a 野quality control冶 mechanism to reduce the likelihood of misfolding and loss of function [79] . The third section describes why protein folding is only one part of the broader mechanism of proteostasis (protein homeostasis) [10] ( Figure 1) , by which proteins in the cell are constantly degraded and created anew, and that degradation is a specific ATPdependent process occurring in the ubiquitinproteosome system. The fourth section describes the current evolving understanding linking these cellular processes and cancer. The first clue to this link between proteostasis and cancer emerged in 1981, when HSPs were first linked to cancer by Oppermann . [11] , who found that HSP90 coimmunoprecipitated with the src oncogene protein. Another observation linking these proteostasis processes to cancer is that, while most proteins have cellular halflives of 12 h, many oncogene proteins and TSG proteins have halflives of a few minutes. Of a particular note, P53, which has been nicknamed the 野guardian of the genome冶 for its role in DNA repair and is a protein that is mutated in over 50% of all cancers, has a halflife of only 20 min. P53 is constantly being synthesized, folded, and degraded, and its halflife is extended in response to various cellular stresses [1215] . The final section concludes by describing how this understanding that linking protein folding, proteostasis, and cancer may point to future directions in the discovery and development of cancer chemotherapy.
Protein Folding in vitro
The 野hallmarks of cancer冶 are all phenotypic [16] . Yet the standard perspective states 野cancer is a disease of the genes冶 [17] , which places the focus purely on the genotype. In the perspective presented here, it does not suffice to focus purely on the genotype要we must also understand the means by which the phenotype results from the genotype, both in the cases where the genotype is normal and in those cases where the genotype has undergone changes that characteristic of cancer [18] . Protein folding and proteostasis are the central mechanisms by which the phenotype emerges from the genotype. In this section, we delve into how protein folding functions (pathway #1, Figure 1 ), that is, when the genome is pristine and is in a state that does not yet require the cellular apparatus designed to assist folding under stress conditions. With this as background knowledge, we can proceed in following sections to elaborate how protein folding functions , under stress conditions such as elevated temperature or Figure 1 . Proteostasis (protein homeostasis). Proteins in a cell are constantly undergoing renewal, as proteins are degraded and synthesized anew. As proteins are synthesized, they must fold properly to acquire their native, functional form (pathway 1). When this protein folding process misfunctions, misfolded proteins arise (pathway 2). Misfolded proteins may either eventually be converted into properly folded proteins (pathway 3) or be degraded (pathway 4). Native, functional proteins can either spontaneously misfold or undergo degradation (unlabeled pathways).
mutations, and explore how this may relate to cancer.
Christian Anfinsen shared the 1972 Nobel Prize in Chemistry for his work on protein folding. His Nobel lecture, 野Studies on the principles that govern the folding of protein chains冶 [19] , succinctly describes conclusions that set the paradigm for protein folding to this day. Figure 2 conveys this general idea of protein folding. A random conformation of a polypeptide chain in an aqueous environment will acquire a specific, unique 3D conformation. With a modest increase in temperature, a protein will lose its original 3D structure but will recover it when the temperature returns to normal. With modest increases in temperature (1益2益), this mild denaturation is reversible. At extremely high temperatures, however, this conformation will turn into a random set of conformations, and it may not revert to the original 3D structure because of denaturation (as in cooking an egg).
Anfinsen studied the protein ribonuclease, with its multiple disulfide bridges, and focused on the reversibility of its heatinduced denaturation. Based on these results, he concluded that the primary sequence of a protein completely determines its 3D conformation, and that the process of protein folding was based strictly on thermodynamics. He phrased this the 野thermodynamic hypothesis冶: 野This hypothesis states that the threedimensional structure of a native protein in its normal physiological milieu (solvent, pH, ionic strength, presence of other components such as metal ions or prosthetic groups, temperature, etc.) is the one in which the Gibbs free energy of the whole system is lowest; that is, that the native conformation is determined by the totality of interatomic interactions and hence by the amino acid sequence, in a given environment.冶 [19] From this thermodynamic hypothesis, Anfinsen also concluded that the 3D structure would not be significantly altered by mutations of residues on the surface of a protein, or mutations of an inner residue when changed to a residue of comparable size, hydrophobicity, etc. Conversely, mutations on inner residues which change the size or hydrophobicity (e.g. an Ala 邛 Glu or an Ala 邛 Ser mutation) had potential to alter the folding from the wildtype 3D structure [19] . Even with Anfinsen爷s thermodynamic hypothesis, the kinetics of protein folding, the rate at which this thermodynamic optimum is achieved, remains a puzzle. The number of conformations that should be sampled from a polypeptide chain to find the correct 3D conformation is astronomical, greater than the number of atoms in the universe. The 野Levinthal爷s paradox冶 is the name given to the puzzling question of how a protein can fold in a few minutes, given the vast number of conformations randomly sampled [20] . Whereas Anfinsen assumed there must be some types of 野nucleation冶 events (small subsequences folding into specific 3D structures which 野seed冶 the formation of the full protein structure), subsequent theoretical [21] and experimental [22] studies on the kinetics of protein folding led to the notion Figure 3A) . The notion that a folding pathway is funnelshaped means that a huge number of conformations are initially explored by many paths in parallel (wide top of the funnel), with a steady winnowing out of the leastpromising sets of conformations (middle of the funnel) and final selection of the thermodynamic optimum proceeding via a small number of folding pathways (bottom of the funnel). This notion of folding funnels explains Levinthal爷s paradox. Figure 3A illustrates a smooth folding funnel that pertains to small proteins, ones which fold extremely fast in a few microseconds, near the theoretical folding 野speed limit冶 [23] . The smooth funnel indicates that there are few if any 野kinetic traps冶, namely conformations that are stable but will not lead to the final global thermodynamic optimum. Figure 3B depicts a 野rugged landscape冶, a protein folding funnel with many kinetic traps. As shown in Figure 3C , if dependent solely on random motion of molecules, it would take a long time for the rare occurrence that will permit a conformation to jump out of this trap. Figure 4 shows a schematic of what such a kinetic trap might look like; one pair of hydrophobic interactions is satisfied in a way that doesn't permit the other pair to form.
Another insight that emerged from recent theoretical studies of protein folding is that the dominant driving force consists of hydrophobic interactions, the tendency for hydrophobic sidechains (Val, Leu, Ile, Ala, Phe, Tyr, Trp) to escape an aqueous environment and seclude themselves with similarly hydrophobic sidechains in a hydrophobic interior要野hydrophobic collapse冶. Pauling made the spectacular prediction of the alphahelix, as a regular motif for protein structures a decade before the first experimental structure was elucidated. This was based on the assumption that hydrogenbonds would form along backbone peptide units spaced three Figure 3 . Protein鄄 folding funnels. These cartoons depict the energy landscape which a folding polypeptide chain must follow in vitro to achieve its final native form. A, depicts a smooth folding funnel, where folding is all 野downhill冶 with no energy barriers stopping intermediate states from folding spontaneously into the final, native form (野kinetic traps冶). Small proteins, which fold very rapidly, generally have this type of folding funnel. B, illustrates a rugged folding funnel with many kinetic traps, i.e. multiple energy barriers exist to stop intermediate states from folding spontaneously into the final form. These rugged landscapes are common for larger proteins. C, shows a one鄄 dimensional slice depicting that kinetically鄄 trapped folding intermediates must surmount the energy barrier through a rugged folding funnel to achieve the final, native form. residues apart. By contrast, it is now thought that helices (and other elements of secondary structures) begin to form as a result of constraints imposed by hydrophobic collapse, with hydrogenbonds rigidifying these helices but their overall effect being secondary to the much stronger hydrophobic forces [24] . An interesting test of Anfinsen爷s hypothesis was done in 1992, when a series of Damino acids (mirror image of standard Lamino acids) were chemically linked according to the sequence of human immunodeficiency virus (HIV) protease. As expected, this led to a protein that was in every way the mirror image of the native HIV protease: it cleaved mirror image substrates with the same specificity, it bound mirror image inhibitors with the same affinity, achiral physicochemical measurements were the same, and chiral ones were of the opposite sign [25] . This section on protein folding concludes with the observation that the types of conformations shown in Figure 4 are prone to aggregation, as depicted in Figure 5 . When hydrophobic elements are exposed on the surface of a protein, they may interact with hydrophobic elements of other proteins to escape the aqueous environment. When multiple such surfaceexposed hydrophobic elements are present, the potential exists for protein aggregation, forming insoluble aggregates that are often toxic to cells [26] .
Protein Folding in vivo
Protein folding is quite different from that .
[27] For medium to largesized proteins it occurs much faster than one might expect, typically in the range of milliseconds to seconds [7] . It takes place in the crowded internal environment of the cell, where many intermolecular interactions could potentially disrupt the normal protein folding pathway. Protein folding is facilitated by chaperones, also known as HSPs or stress proteins.
HSPs were first isolated in 1975 by Lindquist [28] . The first speculation about the function of HSPs evidently was published in 1986 by Pelham [29] in a breathtaking leap of insight. He had found that the heatshocked nucleoli recovered more rapidly after overexpression of HSP70 in an ATPdependent manner. Pelham爷s model 野proposes that during heat shock, proteins become partially denatured, exposing hydrophobic regions which then interact to form insoluble aggregates. By binding tightly to hydrophobic surfaces, HSP70 limits such interactions and promotes disaggregation冶. The term 野chaperone冶 was coined shortly thereafter by Ellis [30] . By the early 1990爷s, the general importance of this mechanism for protein folding was clear [27] . The proportion of proteins that spontaneously fold in the cell is thought to be approximately 10%; the rest rely on chaperoned folding [7] . Chaperones are highly conserved, being present in prokaryotes and eukaryotes, and, as I will note below, are important for the folding of the equally conserved oncogenes and tumor suppressor genes. Chaperones are ubiquitous and upregulated in response to a variety of cell stresses, such as heat, mutations, heavy metals, etc. Chaperones constitute 1%2% of the total weight of proteins in a cell, and they range in size from the 1530 kDa 野small HSPs冶 [31] , to the over 100kDa HSP100/ClP family [32] . Chaperoned protein folding occurs in many ways. At the most abstract level, one can think of them as converting a rugged protein folding funnel into a smooth one, eliminating kinetic traps and speeding up achievement of the thermodynamic optimum [7] . This leads to a profound proposition concerning the role of HSPs in cellular evolution, namely that HSPs act as a buffer, hiding the natural phenotypic variations present in cells, which are unmasked in response to stress [8] . In this view, HSPs expedite the cell爷s ability to evolve in response to stress. For example, HSP70 overexpression has been shown to correlate with certain types of drug resistance, as a response to the stress of drug therapy [33] . HSPs act as a buffer in four stages [7] ( Figure 6 ): (1) as the nascent polypeptide chain emerges from the ribosome, chaperones protect it from premature folding; (2) the polypeptide chain acquires the approximate overall 3D conformation; (3) the polypeptide chain iteratively folds and refolds in a confined 野cage冶 until the final 3D conformation is achieved. In addition, it may make sense to describe a fourth category; and (4) Figure 5 . A schematic example of how protein aggregates may form from misfolded conformations when they leave hydrophobic groups exposed on the surface. (1) In bacteria, a chaperone called the Trigger Factor (TF) is found proximal to the ribosome and protects the nascent chain from premature folding. In eukaryotes, the homologous factor is the ribosomeassociated complex (RAC), sometimes in association with nascent chainassociated complex (NAC). The protection is a necessary step, as ribosomal synthesis occurs at a rate of about 10 residues/sec, whereas the rate of folding is 10 residues/microsec. (2) In eukaryotes, as the full protein is released from the ribosome, HSP40 and HSP70 assist in ensuring the overall 3D conformation is approximately achieved.
(3) The final stage of folding occurs iteratively, in which the partiallyfolded protein interacts with a chaperone and is then released. One way this is accomplished is by the prefolded protein entering the cavity of barrelshaped complexes termed GroES/GroEL in bacteria and TriC/CCT in eukaryotes (Figure 7 ). This creates a protected environment in which the protein can properly fold in a way that may be understood conceptually as an 野Anfinsen cage冶, where the compact environment limits the range of possible extended conformations that may be sampled. The involved chaperones are called chaperonins. Another path in this final stage of folding is via interactions with HSP90, a dimeric protein with each monomer containing three regions: an Nterminal ATPbinding domain, a linker, and a Cterminal dimerization domain (Figure 8 ). The precise nature of HSP90 interactions with a prefolded protein has not been resolved.
(4) Members of the HSP100/ClP family of chaperones appear to interact with misfolded and/or aggregated protein, in effect undoing the damage. As part of a broad network of chaperones, they appear to be able to disassemble stable complexes; to unfold highly stable native protein domains; and to help to resolubilize and refold nonnative proteins trapped in a high molecular weight aggregate [32] . The function of HSP104 has been described as a 野molecular crowbar冶 [34] : it functions by prying apart aggregates. HSP104, which has multiple binding sites, can bind multiple components within the same aggregate. The HSP104 domains that contact the aggregate undergo an ATPdriven conformational change that separates or further unfolds the misfolded aggregates and then releases them. Newly exposed hydrophobic elements, shielded by chaperones such as HSP70 and HSP40, are transiently protected from reaggregation. HSP104 acts iteratively, eventually resulting in the release of HSP70bound folding intermediates that have a renewed opportunity to proceed to the native state.
From the perspective of identifying novel drug targets for cancer, this multiplicity of HSPs throughout protein folding provides many opportunities for modulating these stages of folding with therapeutic agents. Agents targeting HSP90 have been tested in phase III clinical trials [5] , whereas HSP70 is still in basic research phase [35] . There are seemingly endless variations on the overall proteinfolding processes as outlined above. Transporting the protein across membranes may require one prefolded conformation; final folding then occurs after the protein is in the target organelle (e.g. the endoplasmic reticulum) [36] . Exemplified by estrogen receptor, final folding occurs only when that protein is in complex with HSP90 and other factors, and its ligand, progesterone ( Figure 9 ). HSP90 forms complexes with many distinct factors, probably explaining its ability to assist the folding of a huge variety of proteins, such as p53 [6] .
Protein Degradation
The previous sections discussed the processes by which proteins are created, and acquire their functional 3D structure. We now turn to the complementary process of protein degradation. Cellular proteolysis was once viewed as a nonspecific process要the 野garbage collection冶 of the cell. Once it became clear that proteins constantly turn over, with degradation occurring rapidly, specifically, and in an ATPdependent manner, attention focused on the processes of protein degradation. This ultimately led to the isolation of a cellfree system for ATPdependent proteolysis in 1978 [37] , now called the ubiquitinproteasome system (UPS), which is responsible for most proteolysis in the cell.
Attention was drawn to the UPS as a cancer drug target by the 2003 approval of the proteosome inhibitor Velcade/bortemozib for multiple myeloma. One year later, the discovery of the UPS was rewarded by the Nobel Prize to Ciechanover, Hershko, and Rose; their lectures represent a concise introduction to this system [3840] . The proteolytic machinery of the UPS is comprised of the proteosome, a 2.5MDa multicomponent system consisting of a barrelshaped 20S catalytic core particle with a 19S regulatory particle capping both sides of the core particle (Figure 10) . A protein tagged with a polyubiquitin tail is recognized by the proteosome and unfolded near the cap, with proteolysis occurring deeply within the core particle [41] . Tagging for protein degradation is accomplished in a series of steps, ultimately resulting in a polyubiquitin sequence tag covalently attached to a lysine of the substrate protein [42] . This pathway, summarized in Figure  11 , involves a series of enzymes: E1 (ubiquitinactivating enzyme), E2 (ubiquitinconjugating enzyme), and E3 (ubiquitinprotein ligase).
Step 1 creates a covalent linkage between E1 and ubiquitin.
Step 2 uses the E1ubiquitin complex, E2, E3, and S (the substrate protein to be tagged for degradation), to form the complex Ubi.E2.E3.S.
Step 3 repeatedly appends additional ubiquitin molecules to the complex Ubi.E2.E3.S.
Step 4 cleaves this polyubiquitinated complex to form the final tagged substrate, recognized by the proteosome.
The UPS is also becoming recognized as an important component that is involved in biological processes which are related to a variety of disorders with cancerrelated phenotypes. One example is vonHippelLindau (VHL) syndrome, which is a rare autosomaldominant condition with hemangioblastomas in the kidneys, retina, cerebellum, and spinal cord, resulting from a mutation in the VHL tumor suppressor gene. The mechanism by which VHL gene functions involves the UPS, whereby the protein product of this gene interacts with the hypoxiainducible factor1 (HIF1) in response to the cell stress of insufficient oxygen 
Intermediate complex
Protein folding and cancer (hypoxia) [43] . Under normal conditions, in the presence of oxygen, HIF1 is synthesized, rapidly converted into a form which is recognized by pVHL (the protein product of the VHL gene), and subjected to ubiquitination and proteosomal degradation, with an overall halflife of 10 min. Under hypoxic conditions, HIF1 remains in a form not recognized by pVHL, and hence is not degraded. Thus HIF1 is free to promote transcription of genes such as vascular endothelial growth factor (VEGF), a feedback signaling factor that promotes vascularization to facilitate the return to normal conditions (Figure 12 ). Another point of interest about pVHL degradation is that chaperones can be involved: e.g. chaperone HSP90 is not involved in VHL folding but is essential for its degradation [44] . This is an intriguing example of where chaperones are involved in the degradation process rather than the protein folding process; and, here, degradation of a protein involved in a disease is associated with cancer formation, and links proteostasis with cancer and with chaperones in particular.
The UPS also plays a key role in regulating cellular levels of P53, with a halflife of only 20 min in normal cells [14] . P53 is the protein which functions as the 野guardian of the genome冶, and is mutated in over half of all cancers. In response to DNA damage stress such as ultraviolet radiation, p53 levels rise and cells are driven to apoptosis (programmed cell death). P53 acts as a transcription factor that induces the expression of many genes, one of which is mdm2, that codes for a protein Mdm2 that shepherds translocation of P53 from the nucleus to the UPS for degradation. This feedback loop has a transcriptional delay that ensures a brief burst of elevated P53 levels in response to stress.
A final point on the UPS is that misfolded proteins are subjected to a higher rate of degradation than are normal proteins, but these recognition processes are incompletely understood. How the cell distinguishes properlyfolded proteins from misfolded ones, given its complexity, is an intellectually fascinating puzzle. It is difficult to even imagine all the types of molecular recognition processes that must be involved to maintain a careful balance.
Connections to Cancer
We recently have been reminded 野all cancers arise as a result of changes that have occurred in the DNA sequence of the genomes of cancer cells冶 [45] . This, however, remains a hypothesis, not a fact. An Figure 11 . Steps leading to the poly鄄 ubiquitin tag. This pathway involves a series of enzymes: E1 (ubiquitin鄄 activating enzyme), E2 (ubiquitin鄄 conjugating enzyme), and E3 (ubiquitin鄄 protein ligase).
Step 2 uses the E1鄄 ubiquitin complex, E2, E3, and S (the substrate protein to be tagged for degradation) to form the complex Ubi.E2.E3.S.
Step 4 leads to ultimate degradation by the proteosome. alternative, and perhaps an impo rtant addition, to this hypothesis would be to consider and focus on the dynamic cellular processes centered on the proteome, and the process of proteostasis outlined above. The links between chaperones and cancer were first identified almost 30 years ago, and the evidence continues to grow, indicating that chaperones and protein homeostasis likely play an important role in cancer formation, and thus, present multiple opportunities for therapeutic intervention.
In 1981, shortly after the discovery of oncogenes, researchers observed that HSPs coimmunoprecipitated with the src oncogene [11] . The authors concluded 野it would also seem wise to search for other overlaps between the heat shock response and virusinduced neoplastic transformation冶, a suggestion that was not immediately embraced. A dramatic leap forward occurred in 1994 when Whitesell . [46] identified the mechanism of geldanamycininduced reversal of the neoplastic transformation as inhibition of HSP90. Many HSP90 inhibitors are now undergoing evaluation in clinical trials [4749] . The 2003 approval of the proteosome inhibitor Velcade/bortemozib for multiple myeloma further supports the UPS as a cancer drug target [4] . Many other clues support this link to cancer. The list of client proteins of HSP90要those proteins require HSP90 for proper folding要is replete with wellknown oncogenes and tumor suppressor genes: src, AKT, BcrAbl, etc [50] . HSP90 levels often are higher in cancer cells than in normal cells, and HSP expression in breast or gastric cancer is associated with poor prognosis and resistance to chemotherapy or radiotherapy [51] . HSP90 inhibitors have been shown to be synergistic with other chemotherapeutic agents.
[52] The connections between the hemangioblastomas of VHL syndrome and HSP90's involvement in pVHL degradation were mentioned above. Other HSPs are also suspected to be involved in cancer formation: e.g. downregulation of HSP70 has been shown to increase apo ptosis in cancer cells, while leave normal cells unaffected [53] 要which raises an intriguing idea of considering HSP70 as a potential cancerspecific target.
Other drug targets are emerging from increased understanding of proteostasis. Mdm2, mentioned above as a protein involved in P53 degradation, is one example: inhibitors (nutlins) of the P53/Mdm2 interaction were reported in 2004 to shrink tumors in xenograft models [54] . NEDD8 is another protein involved in the UPS; inhibitors of the enzyme which activates NEDD8 were recently found to be effective in suppressing the growth of human tumor xenografts in mice [55] . The homeostatic regulation of P53 illuminates how the dual processes of protein synthesis/folding and protein degradation may be directly connected to neoplastic transformation. The 20min halflife of P53 in the cell is unusually short and its levels, regulated by proteostasis, rise very quickly in response to stressors even though its mRNA levels remain constant [14] . Mutations in p53 gene are found in 30% 50 % of all cancers, and the mutations predominate in a particular class, i.e. point mutations in its DNAbinding domain [13] . Chaperoned folding of P53 is especially complex, involving a variety of cochaperones [6] . It may be that chaperoned folding protects mutant p53 from degradation as well. Cancer cells, even those homozygous for mutations in p53, often have high levels of P53, which may facilitate a variety of mutationinduced mechanisms to run amok [14] . In this regard, application of HSP90 inhibitors has been demonstrated to lower P53 levels and induce apoptosis.
In 1994, Whitesell .
[46] identified the mechanism of geldanamycininduced reversal of the neoplastic transformation as inhibition of HSP90. In 1998, Rutherford and Lindquist [8] suggested that HSPs serve as a capacitor to buffer phenotypic variation. Taking these two findings together, Whitesell and Lindquist [6] have proposed a novel theory of cancer, centered on the role of chaperones. HSP90 can conceal inherent genetic variation within populations of cells, allowing polymorphic variants of crucial signaling pathways to accumulate cryptically while the overall normal phenotype is maintained. This 野buffering冶 capacity of HSP90 funnels complex developmental processes into discrete outcomes despite underlying genotypic variations. Under stress, some of the unstable HSP90 clients may become more unstable, increasing the demand for HSP90 to facilitate refolding of its usual clients and that of these new stressdestabilized proteins. New phenotypes can emerge when this buffering capacity of HSP90 is exceeded, exposing previously hidden genetic variations to natural selection. In cancer, HSP90 might function as a buffer of the extensive genetic heterogeneity common to cancer. Furthermore, Whitesell and Lindquist [6] explain 野HSP90 has a more complex role in facilitating neoplastic transformation than simply inhibiting apoptosis. The dynamic, lowaffinity interactions of HSP90 with its client proteins要such as hormone receptors, transcription factors and kinases要maintain them in a latent but readily activated state. Oncogenic mutation of such clients, however, leads to higher requirements for HSP90 function, presumably because of an exaggerated conformational instability of the mutant.冶 Implications for Chemotherapy 野Molecular targeting冶要using genetic information that links specific proteins to cancer要has led to one spectacular success: Novartis爷 Gleevec is effective against CML, a disease linked to the Philadelphia chromosome with a frequency exceeding 95% [56] . Approved in 2001 to much justifiable acclaim, Gleevec promised to be a harbinger of a new wave of molecularlytargeted therapeutics要the 野magic bullet冶 for CML, designed to inhibit the tyrosine kinase BcrAbl, the oncogene activated via the Philadelphia chromosome. Even oncology researchers at Novartis now conclude that Gleevec may be more an outlier than a standardbearer for the next wave of therapy [57] . Gleevec is the great exception; most new chemotherapies could be considered to be 野neocytotoxics冶 [3] , an unflattering reference to their tendency to show unacceptable toxicity at therapeutic doses (i.e. they have a marginal therapeutic index). Chemotherapy for cancer has the highest attrition rate of any therapeutic area: fewer than 10% of drug candidates entering phase I trials are ultimately approved for commercial use [58] . Fallout in the clinic is primarily due to drug toxicities, i.e. their inability to achieve an advantageous therapeutic index.
If we are to make significant progress against cancer, we need to move beyond developing more neocytotoxics. The standard paradigm often leads to drug candidates that inhibit rapidly dividing cells, which hits both cancer cells and the rapidly dividing cells of the epithelia, leading to the harsh sideeffects of chemotherapy. This approach naturally leads to a low therapeutic index and the duration of efficacy is frequently only 612 months, as cancer cells appear to evolve in response to the selection pressure of the drug.
Whitesell and Lindquist [6] clearly recognized the implications of the theory of cancer:
野Such an evolutionary view of the malignant progression problem suggests that . Consequently, HSP90 might provide a broader, more effective target for anticancer therapies than single, oncogenically activated but dispensable signaling pathways that are the focus of most current drugdiscovery efforts.冶 This is a very provocative suggestion要saying that the key to controlling cancer is to modulate a cell's ability to evolve. This is a testable hypothesis, and one that, if true, would significantly alter our approach towards the discovery and development of chemotherapeutic agents. That cancer cells are hyperevolving may also explain the difficulty in finding chemotherapies whose effectiveness extends beyond 612 months: cancer cells may be evolving away from the selection pressure of a drug.
Conclusions
Appreciating the role of proteostasis in the cell, including the role of chaperones in facilitating proper protein folding and the role of the UPS in protein degradation, yields a novel perspective on cancer, which focuses on the dynamic state of the proteome and the evolving phenotypes of cancer cells. Research on this proteostasis network has yielded one approved drug, with many others undergoing clinical evaluation. We may well be in the early days of fully exploiting protein folding and proteostasis to devise better cancer chemotherapeutic agents.
There are many outstanding questions in this area, the subjects of much current researches:
• How do chaperones recognize improperly folded proteins?
• What is the precise mechanism by which HSP90 inhibition by geldanamycin diminishes P53 levels?
• Would the other HSPs also be attractive drug targets? (HSP70, from early studies, certainly seems of potential interest.)
• Of all possible intervention points in the proteostasis network, which are best for chemotherapy? Which have sites most amenable to inhibition by an orallyavailable 野small molecule冶? Which will provide the best therapy with the least toxicity?
• What is the origin of the therapeutic index of Velcade? What lessons are to be learned by its success as a chemotherapeutic agent?
• What are the full implications of the notion of HSPs爷 buffering evolutionary change? How can this hypothesis be properly evaluated as a theory of the origin of cancer?
• What is the precise mechanism of the neoplastic transformation, and what roles do chaperones specifically play?
Understanding protein misfolding and proteostasis should lead to their exploitation in the development of novel and improved cancer chemotherapeutics.
